

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)**  
**AS AT AND FOR THREE MONTH PERIOD ENDED 30 SEPTEMBER 2024**  
**(FIRST QUARTER)**

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Condensed Consolidated Statement of Financial Position (Unaudited)**  
**As at 30 September 2024**

Particulars	Notes	Amount In BDT	
		30-Sep-24	30-Jun-24
<b>Assets</b>			
<b>Non-Current Assets</b>		<b>36,418,690,660</b>	<b>36,332,123,652</b>
Property, Plant and Equipment	6	20,910,383,573	21,077,115,349
Right of use Assets	7	21,081,406	24,361,873
Capital Work in Progress	8	7,981,259,420	7,163,967,741
Investment in Associates	10	1,570,435,000	2,128,615,000
Other Investments	11	5,935,531,262	5,938,063,689
<b>Current Assets</b>		<b>17,364,389,356</b>	<b>16,853,384,669</b>
Inventories	12	1,790,732,040	1,699,322,929
Trade and Other Receivables	13	14,399,527,777	13,915,714,014
Advances, Deposits & Prepayments	14	1,015,864,735	1,044,796,936
Fixed Deposit with Banks	15	46,526,664	45,820,338
Cash and Cash Equivalents	16	111,738,141	147,730,452
<b>Total Assets</b>		<b>53,783,080,016</b>	<b>53,185,508,321</b>
<b>Shareholders' Equity and Liabilities</b>			
<b>Shareholders' Equity</b>		<b>21,032,331,843</b>	<b>21,539,576,338</b>
Share Capital	17	2,340,000,000	2,340,000,000
Share Premium		8,016,892,026	8,016,892,026
Reserves	18	3,117,448,590	3,683,345,150
Retained Earnings	19	7,557,991,228	7,499,339,162
Non - Controlling Interest	20	1,537,674,930	1,543,272,725
<b>Total Equity</b>		<b>22,570,006,772</b>	<b>23,082,849,063</b>
<b>Non-Current Liabilities</b>		<b>22,836,226,187</b>	<b>22,336,273,004</b>
Provision for Decommissioning of Assets		143,405,563	143,405,563
Long Term Loan	21	22,346,648,853	21,863,720,817
Lease Obligation	22	11,642,496	13,714,468
Deferred Tax Liability	23	334,529,274	315,432,156
<b>Current Liabilities</b>		<b>8,376,847,057</b>	<b>7,766,386,253</b>
Current portion of Long Term loan	21.1	67,349,871	67,349,871
Current Portion of Lease Obligation	22.1	12,453,851	13,943,551
Short term loans	24	520,821,046	556,177,120
Trade and Other Payables	25	7,113,102,666	6,463,692,757
Employee Benefits	26	152,085,465	147,234,452
Unclaimed/Unpaid Dividend		53,866,508	58,675,647
Accrued Expenses	27	457,167,650	459,312,854
<b>Total Equity &amp; Liabilities</b>		<b>53,783,080,016</b>	<b>53,185,508,321</b>
<b>Number of Shares Used to Compute NAV</b>		<b>234,000,000</b>	<b>234,000,000</b>
<b>Net Asset Value (NAV) Including Revaluation Surplus</b>	33	<b>89.88</b>	<b>92.05</b>
<b>Net Asset Value (NAV) Excluding Revaluation Surplus</b>		<b>82.11</b>	<b>84.27</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED**  
**Condensed Statement of Financial Position (Unaudited)**  
**As at 30 September 2024**

Particulars	Notes	Amount In BDT	
		30-Sep-24	30-Jun-24
<b>Assets</b>			
<b>Non-Current Assets</b>		<b>27,888,232,299</b>	<b>27,735,689,008</b>
Property, Plant and Equipment	6a	15,164,425,211	15,265,180,705
Right of use Assets	7	21,081,406	24,361,873
Capital Work in Progress	8	7,981,259,420	7,163,967,741
Investment in Subsidiaries	9	1,017,000,000	1,017,000,000
Investment in Associate	10	1,570,435,000	2,128,615,000
Other Investments	11a	2,134,031,262	2,136,563,689
<b>Current Assets</b>		<b>10,513,595,104</b>	<b>10,716,440,346</b>
Inventories	12a	583,575,546	637,639,101
Trade and Other Receivables	13a	8,873,254,625	8,944,679,482
Advances, Deposits & Prepayments	14a	933,709,141	959,959,975
Fixed Deposit with Banks	15	46,526,664	45,820,338
Cash and Cash Equivalents	16a	76,529,128	128,341,450
<b>Total Assets</b>		<b>38,401,827,403</b>	<b>38,452,129,354</b>
<b>Shareholders' Equity and Liabilities</b>			
<b>Shareholders' Equity</b>		<b>14,164,514,619</b>	<b>14,652,306,216</b>
Share Capital	17	2,340,000,000	2,340,000,000
Share Premium		8,016,892,026	8,016,892,026
Reserves	18a	2,769,800,068	3,333,848,346
Retained Earnings	19a	1,037,822,526	961,565,844
<b>Non-current Liabilities</b>		<b>22,692,820,624</b>	<b>22,192,867,441</b>
Long term loan	21a	22,346,648,853	21,863,720,817
Lease obligation	22	11,642,496	13,714,468
Deferred tax liability	23	334,529,274	315,432,156
<b>Current Liabilities</b>		<b>1,544,492,160</b>	<b>1,606,955,697</b>
Current portion long term loan	21a.1	67,349,871	67,349,871
Current portion of finance lease obligation	22.1	12,453,851	13,943,551
Short term loans	24	520,821,046	556,177,120
Trade and other payables	25a	421,352,639	450,267,403
Employee benefits	26a	55,535,153	50,684,140
Unclaimed/Unpaid Dividend		53,866,508	58,675,647
Accrued expenses	27a	413,113,091	409,857,964
<b>Total Equity &amp; Liabilities</b>		<b>38,401,827,403</b>	<b>38,452,129,354</b>
<b>Number of Shares Used to Compute NAV</b>		<b>234,000,000</b>	<b>234,000,000</b>
<b>Net Asset Value (NAV) Including Revaluation Surplus</b>	33a	<b>60.53</b>	<b>62.62</b>
<b>Net Asset Value (NAV) Excluding Revaluation Surplus</b>		<b>54.75</b>	<b>56.83</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income ( Unaudited)**  
**For Three Month Period Ended 30 September 2024**

Particulars	Notes	Amount In BDT	
		July 2024 to September 2024	July 2023 to September 2023
<b>Revenue from Net Sales</b>	28	<b>1,646,541,812</b>	<b>3,609,651,840</b>
Cost of Goods Sold		(378,398,705)	(418,989,076)
Cost of Power Generation		(819,432,704)	(2,602,494,614)
<b>Gross Profit</b>		<b>448,710,403</b>	<b>588,168,151</b>
<b>Operating Expenses</b>		<b>(318,515,909)</b>	<b>(352,517,206)</b>
General & Administrative Expenses		(118,093,076)	(128,775,286)
Selling & Distribution Expenses		(200,422,834)	(223,741,920)
<b>Profit from Operation</b>		<b>130,194,493</b>	<b>235,650,945</b>
Financial Expenses	29	(55,001,523)	(16,408,665)
Non Operating Income/ (Loss)	30	1,627,604	3,863,577
<b>Net Profit from Operation</b>		<b>76,820,574</b>	<b>223,105,856</b>
Workers Profit Participation Fund		(4,851,013)	(10,624,088)
<b>Net Profit before Tax</b>		<b>71,969,562</b>	<b>212,481,768</b>
<b>Income Tax</b>		<b>(24,563,885)</b>	<b>(35,131,454)</b>
Current Tax (Expenses)/Income	31	(5,002,307)	(40,535,976)
Deferred Tax (Expenses)/Income		(19,561,578)	5,404,523
<b>Net Profit after Tax</b>		<b>47,405,677</b>	<b>177,350,315</b>
Share of Profit from Associate		2,392,200	2,913,877
<b>Net Profit</b>		<b>49,797,877</b>	<b>180,264,192</b>
Less: Non Controlling Interest (share of operating profit)		5,597,796	(3,529,857)
<b>Net Profit after Tax before Other Comprehensive Income</b>		<b>55,395,673</b>	<b>176,734,335</b>
<b>Other Comprehensive Income</b>		<b>(562,641,068)</b>	<b>(22,318,933)</b>
Fair Value Gain of Marketable Securities		(2,533,327)	(159,690)
Fair Value Gain on Investment in Associate		(560,593,192)	(22,229,382)
Share of Other Comprehensive Income		20,992	(176,494)
Deferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Marketable securities		464,459	246,634
<b>Total Comprehensive Income Attributable to Ordinary Shareholders</b>		<b>(507,245,395)</b>	<b>154,415,402</b>
<b>Number of Shares Used to Compute EPS</b>		<b>234,000,000</b>	<b>234,000,000</b>
<b>Earnings Per Share (EPS)</b>	32	<b>0.24</b>	<b>0.76</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

## ORION PHARMA LIMITED

### Condensed Statement of Profit or Loss and Other Comprehensive Income ( Unaudited) For Three Month Period Ended 30 September 2024

Particulars	Notes	Amount In BDT	
		July 2024 to September 2024	July 2023 to September 2023
Revenue from Net Sales	28.a	830,461,674	931,485,437
Cost of Goods Sold		(378,398,705)	(418,989,076)
<b>Gross Profit</b>		<b>452,062,969</b>	<b>512,496,361</b>
<b>Operating Expenses</b>		<b>(301,846,064)</b>	<b>(336,478,419)</b>
General & Administrative Expenses		(101,423,230)	(112,736,500)
Selling & Distribution Expenses		(200,422,834)	(223,741,920)
<b>Profit from Operation</b>		<b>150,216,905</b>	<b>176,017,942</b>
Financial Expenses	29.a	(49,973,240)	(15,896,402)
Non Operating Income/ (Loss)	30.a	1,627,604	3,863,577
<b>Net Profit from Operation</b>		<b>101,871,269</b>	<b>163,985,116</b>
Workers Profit Participation Fund		(4,851,013)	(7,808,815)
<b>Net Profit before Tax</b>		<b>97,020,256</b>	<b>156,176,301</b>
<b>Income Tax</b>		<b>(24,563,885)</b>	<b>(35,131,454)</b>
Current Tax (Expenses)/Income	31	(5,002,307)	(40,535,976)
Deferred Tax (Expenses)/Income		(19,561,578)	5,404,523
<b>Net Profit after Tax</b>		<b>72,456,371</b>	<b>121,044,848</b>
Share of Profit from Associates		2,392,200	2,913,877
<b>Net Profit after Tax before Other Comprehensive Income</b>		<b>74,848,571</b>	<b>123,958,725</b>
<b>Other Comprehensive Income</b>		<b>(562,641,068)</b>	<b>(22,318,933)</b>
Fair Value Gain of Marketable Securities		(2,533,327)	(159,690)
Fair Value Gain on Investment in Associate		(560,593,192)	(22,229,382)
Share of Other Comprehensive Income		20,992	(176,494)
Deferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Marketable securities		464,459	246,634
<b>Total Comprehensive Income attribute to Ordinary Shareholders</b>		<b>(487,792,497)</b>	<b>101,639,792</b>
<b>Number of Shares Used to Compute EPS</b>		<b>234,000,000</b>	<b>234,000,000</b>
<b>Earnings Per Share (EPS)</b>	32.a	<b>0.32</b>	<b>0.53</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Condensed Consolidated Statement of Changes in Equity (Unaudited)**  
**For Three Month Period Ended 30 September 2024**

Amount in BDT

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total	Non controlling Interest	Total
<b>Balance at 01 July 2024</b>	2,340,000,000	8,016,892,026	3,683,345,150	7,499,339,162	21,539,576,338	1,543,272,725	23,082,849,063
Net Profit after Tax	-	-	-	55,395,673	55,395,673	(5,597,796)	49,797,877
Fair Value Gain / (Loss) on Investment in Associate			(560,593,192)	-	(560,593,192)	-	(560,593,192)
Fair Value (Loss)/Gain on Marketable Securities			(2,533,327)	-	(2,533,327)	-	(2,533,327)
Adjustment for sale of Mkt. Securities			900	-	900	-	900
Share of Other Comprehensive Income			20,992	-	20,992	-	20,992
Adjustment of Deferred tax on Revaluation Surplus			464,459	-	464,459	-	464,459
Depreciation on Revaluation Surplus			(3,256,392)	3,256,392	-	-	-
<b>Balance at 30 September 2024</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>3,117,448,590</b>	<b>7,557,991,228</b>	<b>21,032,331,843</b>	<b>1,537,674,929</b>	<b>22,570,006,772</b>

**For Three Month Period Ended 30 September 2023**

Amount in BDT

Particulars	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total	Non controlling Interest	Total
<b>Balance at 01 July 2023</b>	2,340,000,000	8,016,892,026	3,067,212,663	7,400,327,363	20,824,432,052	1,509,624,870	22,334,056,922
Net Profit after Tax	-	-	-	176,734,335	176,734,335	3,529,857	180,264,192
Fair Value Gain / (Loss) on Investment in Associate			(22,229,382)	-	(22,229,382)	-	(22,229,382)
Fair Value (Loss)/Gain on Marketable Securities			(159,690)	-	(159,690)	-	(159,690)
Adjustment for sale of Mkt. Securities			40,203	-	40,203	-	40,203
Share of Other Comprehensive Income			(176,494)	-	(176,494)	-	(176,494)
Adjustment of Deferred tax on Revaluation Surplus			246,634	-	246,634	-	246,634
Depreciation on Revaluation Surplus			(3,510,127)	3,510,127	-	-	-
<b>Balance at 30 September 2023</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>3,041,423,806</b>	<b>7,580,571,825</b>	<b>20,978,887,656</b>	<b>1,513,154,727</b>	<b>22,492,042,383</b>

Sd-  
Chairman

Sd-  
Managing Director

Sd-  
Director

Sd-  
Chief Financial Officer

Sd-  
Company Secretary

**ORION PHARMA LIMITED**  
**Condensed Statement of Changes in Equity (Unaudited)**  
**For Three Month Period Ended 30 September 2024**

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
<b>Balance at 01 July 2024</b>	2,340,000,000	8,016,892,026	3,333,848,346	961,565,844	14,652,306,216
Net Profit after Tax	-	-	-	74,848,571	74,848,571
Fair Value Gain / (Loss) on Investment in Associate	-	-	(560,593,192)	-	560,593,192
Fair Value (Loss)/Gain on Marketable Securities	-	-	(2,533,327)	-	(2,533,327)
Adjustment for sale of Mkt. Securities	-	-	900	-	900
Share of Other Comprehensive Income	-	-	20,992	-	20,992
Adjustment of Deferred tax on Revaluation Surplus	-	-	464,459	-	464,459
Depreciation on Revaluation Surplus	-	-	(1,408,111)	1,408,111	-
<b>Balance at 30 September 2024</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>2,769,800,068</b>	<b>1,037,822,526</b>	<b>14,164,514,619</b>

**For Three Month Period Ended 30 September 2023**

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
<b>Balance at 01 July 2023</b>	2,340,000,000	8,016,892,026	2,709,933,620	973,857,096	14,040,682,742
Net Profit after Tax	-	-	-	123,958,725	123,958,725
Fair Value Gain / (Loss) on Investment in Associate	-	-	(22,229,382)	-	(22,229,382)
Fair Value (Loss)/Gain on Marketable Securities	-	-	(159,690)	-	(159,690)
Adjustment for sale of Mkt. Securities	-	-	40,203	-	40,203
Share of Other Comprehensive Income	-	-	(176,494)	-	(176,494)
Adjustment of Deferred tax on Revaluation Surplus	-	-	246,634	-	246,634
Depreciation on Revaluation Surplus	-	-	(1,564,568)	1,564,568	-
<b>Balance at 30 September 2023</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>2,686,090,322</b>	<b>1,099,380,388</b>	<b>14,142,362,737</b>

Sd-  
Chairman

Sd-  
Managing Director

Sd-  
Director

Sd-  
Chief Financial Officer

Sd-  
Company Secretary

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Condensed Consolidated Statement of Cash Flows ( Unaudited)**  
**For Three Month Period Ended 30 September 2024**

Particulars	Amount In BDT	
	July 2024 to September 2024	July 2023 to September 2023
<b>A. Cash Flows from Operating Activities :</b>		
Cash Received from Customers	1,151,188,570	2,683,848,820
Cash Paid to Suppliers	(462,747,094)	(1,704,435,399)
Cash Payment for Operating Expenses	(244,438,110)	(9,305,608)
<b>Cash Generated from Operation</b>	<b>444,003,366</b>	<b>970,107,813</b>
Income Taxes Paid	(11,060,095)	(60,590,854)
<b>Net Cash Generated/(Used) from Operating Activities</b>	<b>432,943,271</b>	<b>909,516,959</b>
<b>B. Cash Flows from Investing Activities :</b>		
Acquisition of Property, Plant & Equipment	(40,090,872)	(1,171,056)
Capital Work in Progress	(817,291,679)	(955,712,252)
Investment in Subsidiaries, Associate & Others	11,221,149	119,451,357
Interest, Dividend & Other Income	1,627,603	3,863,576
<b>Net Cash Received/(Used) from Investing Activities</b>	<b>(844,533,799)</b>	<b>(833,568,375)</b>
<b>C. Cash Flows from Financing Activities :</b>		
Long Term Loan Received/ (Repaid)	482,928,036	(1,099,392,823)
Short Term Loan Received/ (Repaid)	(43,957,487)	1,108,144,545
Lease obligation	(3,561,672)	(6,054,738)
Financial expenses paid	(55,001,523)	(16,408,665)
Dividend paid	(4,809,139)	(231,434)
<b>Net Cash Received/(Used) from Financing Activities</b>	<b>375,598,216</b>	<b>(13,943,115)</b>
<b>Net Increase /(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(35,992,313)</b>	<b>62,005,469</b>
Cash & Cash Equivalents at the beginning of the period	147,730,453	130,107,383
Cash & Cash Equivalents at the end of the period	<b>111,738,141</b>	<b>192,112,853</b>
<b>Number of Shares Used to Compute NOCFPS</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Net Operating Cash Flow Per Share</b>	<b>34.1 1.85</b>	<b>3.89</b>

Sd-  
Chairman

Sd-  
Managing Director

Sd-  
Director

Sd-  
Chief Financial Officer

Sd-  
Company Secretary



**ORION PHARMA LIMITED**  
**Condensed Statement of Cash Flows ( Unaudited)**  
**For Three Month Period Ended 30 September 2024**

Particulars	Amount In BDT	
	July 2024 to September 2024	July 2023 to September 2023
<b>A. Cash Flows from Operating Activities :</b>		
Cash Received from Customers	889,959,057	961,463,207
Cash paid to Suppliers	(230,967,286)	(244,570,818)
Cash Payment for Operating Expenses	(244,438,109)	(9,305,607)
<b>Cash Generated from Operation</b>	<b>414,553,661</b>	<b>707,586,782</b>
Income Taxes Paid	(11,060,095)	(60,590,854)
<b>Net Cash Generated/(Used) from Operating Activities</b>	<b>403,493,566</b>	<b>646,995,928</b>
<b>B. Cash Flows from Investing Activities :</b>		
Acquisition of Property, Plant & Equipment	(40,090,872)	(1,171,056)
Capital Work in Progress	(817,291,679)	(955,712,252)
Investment in Subsidiaries, Associate, Securities & Others	11,221,149	119,451,357
Interest, Dividend & Other Income	1,627,604	3,863,577
<b>Net Cash Received/(Used) from Investing Activities</b>	<b>(844,533,799)</b>	<b>(833,568,374)</b>
<b>C. Cash Flows from Financing Activities :</b>		
Long Term Loan Received/ (Repaid)	482,928,036	(818,046,393)
Short Term Loan Received/ (Repaid)	(35,356,074)	1,089,267,778
Lease obligation	(3,561,672)	(6,054,738)
Dividend paid	(4,809,139)	(231,434)
Interest Paid	(49,973,240)	(15,896,402)
<b>Net Cash Received/(Used) from Financing Activities</b>	<b>389,227,911</b>	<b>249,038,811</b>
<b>Net Increase /(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(51,812,321)</b>	<b>62,466,365</b>
Cash & Cash Equivalents at the beginning of the period	128,341,450	24,827,980
<b>Cash &amp; Cash Equivalents at the end of the period</b>	<b>76,529,128</b>	<b>87,294,345</b>
<b>Number of Shares Used to Compute NOCFPS</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Net Operating Cash Flow Per Share</b>	<b>34a.1 1.72</b>	<b>2.76</b>

Sd- Chairman                      Sd- Managing Director                      Sd- Director                      Sd- Chief Financial Officer                      Sd- Company Secretary

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES**  
**Selected Explanatory Notes to the Condensed Consolidated Financial Statements**  
**For Three Month Period Ended 30 September 2024 (First Quarter)**

**1 Reporting Entity**

**1.1 Background of the Entity**

Orion Pharma Limited, earlier called Orion Laboratories Limited was incorporated in 1965 as a private limited company. The Company was converted into a public limited company on 24 July 2010. The registered office of the company is at 153-154, Tejgaon I/A, Dhaka-1208, Bangladesh.

The Company is listed both with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) on 20 March 2013.

**1.2 Nature of Business**

Orion Pharma Limited is engaged in the creation and discovery, development, manufacturing and marketing of pharmaceutical products including vaccines and health-related consumer products.

**1.3 Subsidiary Companies**

**1.3.1 Orion Power Meghnaghat Limited**

Orion Power Meghnaghat Ltd. was incorporated on 30 June 2010 as a public limited company under the Companies Act, 1994 with authorized share capital of Tk. 4,000,000,000 divided into 400,000,000 Ordinary shares of Tk. 10 each. The company implemented a 100 MW HFO Power based Plant on quick rental basis in Meghnaghat, Dhaka to supply electricity to national grid with machineries and equipment supplied by Wartsila OY, Finland. Orion Pharma Ltd. holds 95% of equity share of this company directly.

The company has set up a 100 MW HFO Power Plant on quick rental basis in Meghnaghat, Sonargaon, Narayanganj with machineries and equipment's supplied by Wartsila Finland OY for generation and supply of electricity. The company has signed the contract with Bangladesh Power Development Board (hereinafter referred as BPDB) acting as an off taker to supply power to them solely under the contract No. 09755 executed on June 30, 2010. According to the said contract, the Government will purchase the power for a period of five (5) years commencing from May 08, 2011. The contract has been extended for further five (5) years effective from May 09, 2016 vide memo no- 27.00.0000.071.14.035.2013.535 dated 01 December 2016. The contract then expired on 07 May 2021. The government renewed the contract for two (2) years effective from 24 March 2022 vide memo no – 27.11.0000.101.14.020.22-1697 dated: 10 April 2022. The purpose of this contract is to supply of Net Energy Output, under the terms and conditions provided “No Electricity, No Payment and also without any guaranteed Minimum Off-take” basis by Rental Power Company by BPDB which expired on 23 March 2024. As per memo No.: 27.11.0000.101.14.020.24-1099 dated: 29 April 2024, the company was instructed to resume and continue operation.

**1.3.2 Dutch Bangla Power & Associates Limited**

Dutch Bangla Power & Associates Ltd. was incorporated on 1 July 2010 as a public limited company under the Companies Act, 1994 with authorized share capital of Tk. 1,000,000,000 divided into 100,000,000 ordinary shares of Tk. 10 each. The Company was awarded by the Government of Bangladesh and BPDB to implement 100 MW HFO Power Plant on quick rental basis in Siddhirganj, Narayanganj to supply electricity to national grid with machineries and equipment supplied by Wartsila OY, Finland. Orion Pharma Ltd. holds 67% of equity share of this Company.

The company has set up a 100 MW HFO Power Plant on quick rental basis in Siddhirganj, Narayanganj with machineries and equipments supplied by Wartsila Finland OY for generation and supply of electricity. The company has signed the contract with Bangladesh Power Development Board (hereinafter referred as BPDB) acting as an off taker to supply power to them solely under the contract No. 09756 executed on July 01, 2010. According to the said contract, the Government will purchase the power for a period of five (5) years commencing from July 21, 2011. The contract has been extended for further five (5) years effective from 22 July 2016 vide memo no- 27.00.0000.071.14.122.2010.534 dated 01 December 2016. The contract then expired on 22 July 2021. The government renewed the contract for two (2) years effective from 24 March 2024 vide memo no - 27.11.0000.101.14.020.22-1696 dated: 10 April 2024. The purpose of this contract is to supply of Net Energy Output, under the terms and conditions provided “No Electricity, No Payment and also without any guaranteed Minimum Off-take” basis by Rental Power Company by BPDB which expired on 23 March 2024. As per memo No.: 27.11.0000.101.14.020.24-1100 dated: 29 April 2024, the company was instructed to resume and continue operation.

**1.4 Associate Company**  
**Orion Infusion Limited**

Orion Infusion Limited is a public limited company incorporated in Bangladesh on May 05, 1983 and is now operating under the banner of Orion Group. Other shareholders of the company are sponsor shareholders, foreign investors, financial institutions and general public.

The Company was listed with Dhaka Stock Exchange Limited (DSE) on 05 October 1994 and Chittagong Stock Exchange Limited (CSE) on 22 September 1996. Orion Pharma Ltd. holds 21.76 % of equity share of this company directly.

## 2 Basis of Preparation

### 2.1 Statement of Compliance

These Condensed Interim Financial Statements of the company comprised the company's and its subsidiaries (together referred to as the 'Group' and individually as 'Group entities') and the Group's interest in associates have been prepared in accordance with International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), in particular International Accounting Standard (IAS) 34: *Interim Financial Reporting*, the Companies Act 1994, Securities and Exchange Rules 1987 and other applicable laws and regulations.

### 2.2 Components of the Condensed Financial Statements

According to IAS-34 'Interim Financial Reporting', these interim financial statements include the following components-

- i. Condensed Consolidated Statement of Financial Position
- ii. Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
- iii. Condensed Consolidated Statement of Changes in Equity
- iv. Condensed Consolidated Statement of Cash Flows
- v. Selected Explanatory Notes to the Condensed Consolidated Financial Statements

### 2.3 Basis of Measurement

The financial statements have been prepared on historical cost basis except for certain assets which are stated either at revalued amount or fair market value.

### 2.4 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Taka (Taka/Tk./BDT), which is the company's functional and presentation currency. All amounts have been rounded off to the nearest integer.

### 2.5 Reporting Period

These Condensed Interim Financial Statements of the company cover three month period from 1 July 2024 to 30 September 2024.

### 2.6 Date of Authorization

The financial statements were authorized for issue by the Board of Directors in its meeting held on November 14, 2024 for publication.

### 2.7 Events after the reporting period

#### Information regarding subsidiary companies

For this quarter there was no such issue.

## 3 Accounting Policies and Methods of Computations

The accounting policies and methods of computations followed in preparing these financial statements are same as those used in the annual financial statements prepared and published for the year ended 30 June 2024.

## 4 Subsequent Events

No material events occurred after the reporting date, non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision.

## 5 Acquisition of Property, Plant & Equipments of Orion Pharma Ltd. and its subsidiaries during the Period.

*Discloser as per BSEC Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018.*

SL No.	Particulars	Amount in BDT	
		30-Sep-24	30-Sep-23
i	Land & Land Development	-	-
ii	Factory & Office Building	32,494,170	-
iii	Plant & Machinery	1,572,565	85,330
iv	Furniture & Fixtures	2,659,149	37,270
v	Office Equipment	2,353,883	1,003,510
vi	Road & Road Development	8,920	44,946
	<b>Total</b>	<b>39,088,686</b>	<b>1,171,056</b>

SL No.	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
<b>6.</b>	<b>Property, plant and equipment</b>		
	Opening balance	21,077,115,349	13,317,799,927
	Add: Addition during the period	39,088,686	19,594,222
	Transfer from Capital work in Progress	-	8,310,620,491
	Less: Sale /disposal during the period	-	(57,677)
		<b>21,116,204,035</b>	<b>21,647,956,963</b>
	Less: Depreciation charged during the period	(205,820,463)	(570,841,614)
	<b>Written down value</b>	<b>20,910,383,572</b>	<b>21,077,115,349</b>

<b>6a.</b>	<b>Property, plant and equipment</b>		
	Opening balance	15,265,180,705	7,228,006,743
	Add: Addition during the period	39,088,686	19,442,622
	Transfer from Capital work in Progress	-	8,310,620,491
	Less: Sale /disposal during the period	-	(57,677)
		<b>15,304,269,391</b>	<b>15,558,012,179</b>
	Less: Depreciation charged during the period	(139,844,180)	(292,831,474)
	<b>Written down value</b>	<b>15,164,425,211</b>	<b>15,265,180,705</b>

<b>7.</b>	<b>Right of use assets</b>		
	Opening Balance	143,942,706	143,366,149
	Add: Addition during the period	1,002,186	4,772,731
		<b>144,944,892</b>	<b>148,138,880</b>
	Less: Disposal/ adjustment	-	(4,196,174)
		<b>144,944,892</b>	<b>143,942,706</b>
	Amortization		
	Opening balance	119,580,834	101,726,647
	Addition during the period	4,282,653	17,854,187
		<b>123,863,487</b>	<b>119,580,834</b>
	<b>Written down value</b>	<b>21,081,406</b>	<b>24,361,873</b>

<b>8.</b>	<b>Capital Work in Progress</b>		
	Opening balance	7,163,967,741	13,064,566,507
	Add: Addition during the period	817,291,679	2,410,021,725
	Transfer to Property, plant and equipment	-	(8,310,620,491)
		<b>7,981,259,420</b>	<b>7,163,967,741</b>

Name of the subsidiary company	Number of shares	Share holding (%)	Amount in BDT	
			30-Sep-24	30-Jun-24
Orion Power Meghnaghat Ltd.	95,000,000	95.00	950,000,000	950,000,000
Dutch Bangla Power & Associates Ltd.	6,700,000	67.00	67,000,000	67,000,000
<b>Total</b>			<b>1,017,000,000</b>	<b>1,017,000,000</b>

Investment in subsidiaries are stated at cost.

<b>10.</b>	<b>Investment in associate</b>		
	<b>Orion Infusion Limited</b>		
	Opening balance	2,128,615,000	1,490,695,000
	Add: Share of profit during the period	2,392,200	9,214,400
	Less: Dividend during the period	-	(4,430,000)
	Add: Share of other comprehensive income	20,992	36,999

SL No.	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
	Add: Fair value adjustment	(560,593,192)	633,098,601
		<b>1,570,435,000</b>	<b>2,128,615,000</b>
<b>11.</b>	<b>Other investment</b>		
	Investment in marketable securities (Note 11.1)	13,790,586	16,323,013
	Investment in non-Quoted Shares (Note 11.2)	5,921,740,676	5,921,740,676
		<b>5,935,531,262</b>	<b>5,938,063,689</b>
<b>11.1</b>	<b>Investment in marketable securities</b>		
	AB Investment Limited.	2,990,048	4,248,056
	Bank Asia Securities Limited.	4,213,449	4,905,132
	LankaBangla Securities Ltd.	6,587,089	7,169,825
		<b>13,790,586</b>	<b>16,323,013</b>
<b>11.2</b>	<b>Investment in non-quoted shares</b>		
	Orion Power Khulna Limited.	500,000	500,000
	Orion Power Dhaka Limited.	500,000	500,000
	ICB Islami Bank Limited	246,000	246,000
	Orion Infrastructure Limited.	2,117,209,676	2,117,209,676
	Energon Renewable (BD) Ltd.	1,500,000	1,500,000
	Orion Power Unit - 2 Dhaka Ltd.	3,801,785,000	3,801,785,000
		<b>5,921,740,676</b>	<b>5,921,740,676</b>
<b>11a</b>	<b>Other investment</b>		
	Investment in marketable securities (Note 11a.1)	13,790,586	16,323,013
	Investment in non-Quoted Shares (Note 11a.2)	2,120,240,676	2,120,240,676
		<b>2,134,031,262</b>	<b>2,136,563,689</b>
<b>11a.1</b>	<b>Investment in marketable securities</b>		
	AB Investment Limited.	2,990,048	4,248,056
	Bank Asia Securities Limited.	4,213,449	4,905,132
	LankaBangla Securities Ltd.	6,587,089	7,169,825
		<b>13,790,586</b>	<b>16,323,013</b>
<b>11a.2</b>	<b>Investment in non-quoted shares</b>		
	Orion Power Khulna Limited.	500,000	500,000
	Orion Power Dhaka Limited.	500,000	500,000
	ICB Islami Bank Limited	246,000	246,000
	Orion Infrastructure Limited.	2,117,209,676	2,117,209,676
	Orion Power Unit - 2 Dhaka Ltd.	1,785,000	1,785,000
		<b>2,120,240,676</b>	<b>2,120,240,676</b>
<b>12.</b>	<b>Inventories</b>		
	Raw materials	212,711,810	223,558,583
	Packing materials	63,382,616	112,835,551
	Work-in-process	47,583,427	33,940,589
	Finished goods	138,835,519	152,492,482
	Printing Stationeries	14,575,938	16,169,876
	Promotional materials	22,468,782	26,715,542
	Material in transit	84,017,454	71,926,478
	Spare parts	516,968,898	483,494,642
	Inventory HFO & LFO	690,187,595	578,189,186
		<b>1,790,732,040</b>	<b>1,699,322,929</b>
<b>12.a</b>	<b>Inventories</b>		
	Raw materials	212,711,810	223,558,583
	Packing materials	63,382,616	112,835,551
	Work-in-process	47,583,427	33,940,589
	Finished goods	138,835,519	152,492,482
	Printing Stationeries	14,575,938	16,169,876

SL No.	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
	Promotional materials	22,468,782	26,715,542
	Material in transit	84017453.82	71,926,478
		<b>583,575,546</b>	<b>637,639,101</b>
<b>13.</b>	<b>Trade &amp; other receivables</b>		
	Trade receivables	4,705,430,973	4,210,077,730
	Other receivables (Note-13.1)	9,694,096,804	9,705,636,284
		<b>14,399,527,777</b>	<b>13,915,714,014</b>

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

**Ageing of the above balance is as follows:**

Below 180 days	4,705,430,973	4,210,077,730
Above 180 days	-	-
	<b>4,705,430,973</b>	<b>4,210,077,730</b>

SL. No.	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
I	Trade receivables considered good in respect of which the company is fully secured	4,705,430,973	4,210,077,730
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security	-	-
III	Trade receivables considered doubtful or bad	-	-
IV	Trade receivables due by any director or other officer of the company	-	-
V	Trade receivables due by common management	-	-
VI	The maximum amount of receivable due by any director or other officer of the company	-	-
	<b>Total</b>	<b>4,705,430,973</b>	<b>4,210,077,730</b>

**13.1 Other receivables**

Claim receivables, insurance & others	4,384,176	4,352,154
Dividend receivable	-	4,430,000
Interest on FDR	631,430	578,164
Other receivables	1,220,885,230	1,220,885,230
Current account with other related companies (Note. 13.1.1)	8,468,195,969	8,475,390,736
	<b>9,694,096,804</b>	<b>9,705,636,284</b>

**13.1.1 Current account with other related companies**

Noakhali Gold Food Ltd.	10,859,928	10,859,928
Orion Properties Ltd.	23,550,142	23,550,142
Orion Gas Limited	90,911,272	90,911,272
Orion Power Khulna Ltd.	1,076,950,154	1,084,624,104
Orion Power Dhaka Ltd.	2,370,355,084	2,370,263,896
Jafflong Tea Company Ltd.	73,302,850	73,302,850
Orion Agro Product Ltd.	275,775,350	275,775,350
Interior Accom Consortium Ltd.	85,407,892	85,407,892
Digital Power & Associate Ltd.	1,047,629,195	1,045,385,127
Orion Footwear Ltd.	258,954,807	258,954,807
Panbo Bangla Mashroom Ltd.	38,128,200	38,128,200
Orion Power Unit 2 Dhaka Ltd.	952,331,473	952,331,473
Orion Home Appliance Ltd.	139,697,496	139,697,496
Orion Hospitals Ltd.	26,222,300	26,222,300
Orion Power Rupsha Ltd.	122,429,699	122,929,699
Energion Renewable (BD) Ltd.	683,407,792	683,407,792
Orion Quaderia Textiles Ltd.	187,910,000	187,910,000
Orion Tea Company Ltd	379,357,868	379,357,868
SAZKA Natural Care Ltd.	108,663,500	108,663,500

SL No.	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
	Orion Power Sonargaon Ltd	494,768,967	496,125,040
	Orion Knit Textiles Ltd.	21,582,000	21,582,000
		<b>8,468,195,969</b>	<b>8,475,390,736</b>
<b>13.a</b>	<b>Trade &amp; other receivables</b>		
	Trade receivables	312,821,099	372,318,481
	Other receivables (Note - 13a.1)	8,560,433,527	8,572,361,001
		<b>8,873,254,625</b>	<b>8,944,679,482</b>

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

**Ageing of the above balance is as follows:**

Below 180 days	312,821,099	372,318,481
Above 180 days	-	-
	<b>312,821,099</b>	<b>372,318,481</b>

SL No	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
I	Trade receivables considered good in respect of which the company is fully	312,821,099	372,318,481
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security		-
III	Trade receivables considered doubtful or bad		-
IV	Trade receivables due by any director or other officer of the company		-
V	Trade receivables due by common management		-
VI	The maximum amount of receivable due by any director or other officer of the		-
	<b>Total</b>	<b>312,821,099</b>	<b>372,318,481</b>

**13a.1 Other receivables**

Claim receivables, insurance & others	4,384,176	4,352,154
Dividend receivable	-	4,430,000
Interest on FDR	631,430	578,164
Other receivables	938,766,019	938,766,019
Current account with subsidiaries (13a.1.1)	346,395,908	346,395,908
Current account with other related companies (13a.1.2)	7,270,255,994	7,277,838,756
	<b>8,560,433,527</b>	<b>8,572,361,001</b>

**13a.1.1 Current account with subsidiaries**

Dutch Bangla Power & Associates Limited.	346,395,908	346,395,908
	<b>346,395,908</b>	<b>346,395,908</b>

**13a.1.2 Current account with other related companies**

Orion Properties Ltd.	21,780,585	21,780,585
Orion Power Khulna Ltd.	1,076,950,154	1,084,624,104
Orion Power Dhaka Ltd.	2,284,334,998	2,284,243,810
Interior Accom Consortium Ltd.	118,564,892	118,564,892
Orion Agro Product Ltd.	267,922,512	267,922,512
Orion Power Unit -2 Dhaka Ltd.	1,062,250,503	1,062,250,503
Digital Power & Associates Ltd.	196,111,884	196,111,884
Orion Hospitals Ltd.	21,222,300	21,222,300
Energon Renewables (BD) Ltd.	698,707,792	698,707,792
Orion Home Appliances Ltd.	131,890,000	131,890,000
SAZKA Natural Care Ltd.	108,663,500	108,663,500
Orion Gas Ltd.	41,711,272	41,711,272
Panbo Bangla Mushroom Ltd	38,128,200	38,128,200
Orion Footwear Ltd.	120,292,645	120,292,645



SL No.	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
	Orion Tea Company Ltd	379,357,868	379,357,868
	Orion Power Sonargaon Ltd	501,980,411	501,980,411
	Jafflong Tea Company Ltd.	70,894,479	70,894,479
	Orion Knit Textiles Ltd.	21,582,000	21,582,000
	Orion Quaderia Textiles Ltd	107,910,000	107,910,000
		<b>7,270,255,994</b>	<b>7,277,838,756</b>
<b>14.</b>	<b>Advances, deposits and prepayments</b>		
	<b>Advances:</b>		
	Advance income tax (Note-14.1)	307,035,702	295,975,607
	Advance imprest money	155,500	123,500
	Advance motor cycle	5,819,208	6,437,957
	Advance - car loan	284,808	433,522
	Collection advance	12,189,712	11,097,734
	Advance to C&F agents	9,389,454	6,662,649
	Advance office rent	2,223,742	2,822,634
	Advance against land purchase	97,260,635	97,260,635
	Advance to employee	6,805,205	8,129,682
	Other advance	1,190,687	1,190,687
	Advance Cash Purchase	144,205	852,328
	Advance to Supplier	143,736,800	173,158,820
	Machinery in Transit	177,591,885	185,425,315
		<b>763,827,543</b>	<b>789,571,070</b>
	<b>Deposits:</b>		
	Earnest money	9,833,415	9,808,415
	Security deposit	49,549,749	48,059,193
	Bank guarantee	58,477,623	58,477,623
	L/C Margin & Balance	127,972,434	526,567
	Lease deposit	254,133	127,700,000
		<b>246,087,354</b>	<b>244,571,798</b>
	<b>Prepayments:</b>		
	Insurance premium	465,342	110,830
	Bank guranttee,commission & charge	5,484,495	10,543,237
		<b>5,949,837</b>	<b>10,654,068</b>
		<b>1,015,864,735</b>	<b>1,044,796,936</b>
<b>14.1</b>	<b>Advance income tax</b>		
	Opening balance	295,975,607	253,914,819
	Add: Addition during the period	11,060,095	42,060,789
	Closing balance	<b>307,035,702</b>	<b>295,975,607</b>
<b>14.a</b>	<b>Advances, deposits &amp; prepayments</b>		
	<b>Advances:</b>		
	Advance income tax (Note -14a.1)	304,472,610	293,412,515
	Advance imprest money	155,500	123,500
	Motor cycle advance	5,819,208	6,437,957
	Advance - car loan	284,808	433,522
	Collection advance	12,189,712	11,097,734
	Advance to C&F agents	9,389,454	6,662,649
	Advance office rent	2,223,742	2,822,634
	Advance against land purchase	97,260,635	97,260,635
	Advance to Employee	5,956,262	7,808,198
	Others Advance	1,190,687	1,190,687
	Advance Cash Purchase	144,205	852,328
	Advance Paid to Suppliers	126,029,889	156,947,314

SL No.	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
	Machinery in Transit	177,591,885	185,425,315
		<b>742,708,597</b>	<b>770,474,987</b>
	<b>Deposits</b>		
	Earnest money	9,833,415	9,808,415
	Security deposit	49,549,749	48,059,193
	Bank guarantee	3,663,247	3,663,247
	Lease deposit	254,133	254,133
	L/C Margin & Balance	127,700,000	127,700,000
		<b>191,000,544</b>	<b>189,484,988</b>
		<b>933,709,141</b>	<b>959,959,975</b>
<b>14a.1</b>	<b>Advance income tax</b>		
	Opening balance	293,412,515	251,801,807
	Addition during the period	11,060,095	41,610,707
	<b>Closing balance</b>	<b>304,472,610</b>	<b>293,412,515</b>
<b>15.</b>	<b>Fixed deposit with banks</b>		
	Social Islami Bank Limited., Principal Branch, Dhaka.	10,651,067	10,473,026
	Agrani Bank Ltd.	35,875,597	35,347,312
		<b>46,526,664</b>	<b>45,820,338</b>
<b>16.</b>	<b>Cash &amp; cash equivalents</b>		
	Cash in hand (Note -16.1)	10,883,671	5,608,660
	Cash at B/O account (Note -16.2)	65,522	66,872
		<b>10,949,192</b>	<b>5,675,532</b>
	<b>Balance with banks on account</b>		
	Current account	85,161,967	133,925,252
	Short term deposit account	15,626,982	8,129,669
		<b>100,788,949</b>	<b>142,054,920</b>
		<b>111,738,141</b>	<b>147,730,452</b>
<b>16.1</b>	<b>Cash in hand</b>		
	Head office	2,229,280	2,400,048
	Depot office	8,654,391	3,208,613
		<b>10,883,671</b>	<b>5,608,660</b>
<b>16.2</b>	<b>Cash at B/O account</b>		
	Bank Asia Securities Limited.	19,549	19,999
	Jahan Securities Limited.	624	1,074
	LankaBangla Securities Ltd.	42,249	42,699
	Shanta Securities Ltd.	3,100	3,100
		<b>65,522</b>	<b>66,872</b>
<b>16.a</b>	<b>Cash and cash equivalents</b>		
	Cash in hand (Note -16a.1)	7,430,356	3,394,262
	Cash at B/O account (Note -16a.2)	62,422	63,772
		<b>7,492,777</b>	<b>3,458,034</b>
	<b>Cash at Bank:</b>		
	Current account	53,409,369	116,753,748
	Short term deposit account	15,626,982	8,129,669
		<b>69,036,351</b>	<b>124,883,416</b>
		<b>76,529,128</b>	<b>128,341,450</b>
<b>16a.1</b>	<b>Cash in hand</b>		
	Head office - central cash & main cash	414,952	1,414,262

SL No.	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
	Depot office - petty cash	7,015,404	1,980,000
		<b>7,430,356</b>	<b>3,394,262</b>

#### 16a.2 Cash at B/O account

Bank Asia Securities Limited	19,549	19,999
Jahan Securities Limited	624	1,074
LankaBangla Securities Ltd.	42,249	42,699
	<b>62,422</b>	<b>63,772</b>

#### 17. Share capital

##### Authorized capital

500,000,000 ordinary shares of Tk. 10 each	<b>5,000,000,000</b>	<b>5,000,000,000</b>
--	----------------------	----------------------

##### Issued, subscribed and paid-up capital

234,000,000 ordinary shares of Tk. 10 each	<b>2,340,000,000</b>	<b>2,340,000,000</b>
--	----------------------	----------------------

##### Shareholding position of the company

Range of Shareholding	Number of Shareholders	Number of Shares	% of holding	
			30-Sep-24	30-Jun-24
Up to 500 Shares	29,540	4,321,635	1.85%	1.66%
501 to 5,000 Shares	11,962	21,430,088	9.16%	9.49%
5001 to 10,000 Shares	1,697	12,481,289	5.33%	5.92%
10,001 to 20,000 Shares	949	13,686,489	5.85%	6.53%
20,001 to above	931	182,080,499	77.81%	76.40%
<b>Total</b>	<b>45,079</b>	<b>234000000</b>	<b>100%</b>	<b>100%</b>

Categories of shareholders	Number of Shareholders	Number of Shares	% of holding	
			30-Sep-24	30-Jun-24
Sponsors	5	74,841,600	31.98%	31.98%
Foreign Investor	706	2,757,321	1.18%	0.08%
Financial institutions	486	47,453,722	20.28%	21.56%
General public	43,882	108,947,357	46.56%	46.38%
<b>Total</b>	<b>45,079</b>	<b>234000000</b>	<b>100%</b>	<b>100%</b>

Orion Power Meghnaghat Limited	Number of Shares	Face Value	% of holding	
			30-Sep-24	30-Jun-24
Orion Pharma Limited	95,000,000	950,000,000	95.00%	95.00%
Integral Energy Limited	3,000,000	30,000,000	3.00%	3.00%
Jafflong Tea Company Limited	500,000	5,000,000	0.50%	0.50%
Mr. Mohammad Obaidul Karim	500,000	5,000,000	0.50%	0.50%
Mr. Salman Obaidul Karim	600,000	6,000,000	0.60%	0.60%
Mrs. Arzuda Karim	350,000	3,500,000	0.35%	0.35%
Haarhuis Generation B.V.	50,000	500,000	0.05%	0.05%
<b>Total</b>	<b>100,000,000</b>	<b>1,000,000,000</b>	<b>100%</b>	<b>100%</b>

Dutch Bangla Power & Associates Limited	Number of Shares	Face Value	% of holding	
			30-Sep-24	30-Jun-24
Orion Pharma Limited	6,700,000	67,000,000	67.00%	67.00%
Shenzhen Nanshan Power Co. Ltd.	50,000	500,000	0.50%	0.50%
Mohammad Obaidul Karim	100,000	1,000,000	1.00%	1.00%
Salman Obaidul Karim	3,087,500	30,875,000	30.88%	30.88%
Orion Tea Company Ltd.	50,000	500,000	0.50%	0.50%
Jafflong Tea Co. Ltd.	2,500	25,000	0.03%	0.03%
Mrs. Arzuda Karim	10,000	100,000	0.10%	0.10%

SL No.	Particulars			Amount in BDT	
				30-Sep-24	30-Jun-24
	Total	10,000,000	100,000,000	100%	100%
<b>18. Reserves</b>					
	Fair value gain/(loss) on investment in associate (Note -18.1)			1,473,205,703	2,033,798,895
	Fair value gain /(loss) on marketable securities (Note -18.2)			(13,885,362)	(11,606,178)
	Share of other comprehensive income of associate (Note - 18.3)			6,795,866	6,774,874
	Revaluation surplus on property, plant and equipment (Note -18.4)			1,651,332,384	1,654,377,559
				<b>3,117,448,590</b>	<b>3,683,345,150</b>
<b>18.1 Fair value gain on investment in associate</b>					
	Opening balance			2,033,798,895	1,400,700,294
	Fair value gain/ (loss) during the period			(560,593,192)	633,098,601
				<b>1,473,205,703</b>	<b>2,033,798,895</b>
<b>18.2 Fair value gain/(loss) on marketable securities</b>					
	Opening balance			(11,606,178)	(7,704,833)
	Adjustment of sale of marketable securities			900	2,860,258
	Fair value gain/(loss) on marketable securities (Note - 18.2.1)			(2,533,327)	(7,195,085)
	Transferred to deferred tax assets/(liabilities)			253,243	433,483
				<b>(13,885,362)</b>	<b>(11,606,178)</b>
<b>18.2.1 Fair value gain/(loss) on marketable securities during the period</b>					
	Unrealized gain/(loss) position (closing)			(15,428,180)	(12,895,753)
	Unrealized gain/(loss) position (opening)			(12,895,753)	(8,560,925)
	<b>Total change during the period</b>			<b>(2,532,427)</b>	<b>(4,334,828)</b>
	Fair value adjustment for sale of securities (realized loss)			(900)	(2,860,258)
	<b>Unrealized gain/(loss) during the period</b>			<b>(2,533,327)</b>	<b>(7,195,085)</b>
<b>18.3 Share of other comprehensive income</b>					
	Opening balance			6,774,874	6,737,875
	Add: Addition during the period			20,992	36,999
				<b>6,795,866</b>	<b>6,774,874</b>
<b>18.4 Revaluation surplus on property, plant &amp; equipment</b>					
	Opening balance			1,654,377,559	1,667,479,327
	Adjustment during the period to retained earnings for depreciation			(3,256,392)	(14,040,509)
	Adjustment of deferred tax on revaluation surplus			211,217	938,741
				<b>1,651,332,384</b>	<b>1,654,377,559</b>
<b>18.a Reserve</b>					
	Fair value gain on investment in associates (Note - 18a.1)			1,473,205,703	2,033,798,894
	Fair value gain/(loss) on marketable securities (Note - 18a.2)			(13,885,362)	(11,606,177)
	Share of other comprehensive income (Note - 18a.3)			6,795,866	6,774,874
	Revaluation surplus on property, plant & equipment (Note - 18a.4)			1,303,683,861	1,304,880,755
				<b>2,769,800,068</b>	<b>3,333,848,346</b>
<b>18a.1 Fair value gain on investment in associates</b>					
	Opening balance			2,033,798,894	1,400,700,294

SL No.	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
	Fair value gain/(loss) during the period	(560,593,192)	633,098,601
		<b>1,473,205,703</b>	<b>2,033,798,894</b>
<b>18a.2</b>	<b>Fair value gain/(loss) on marketable securities</b>		
	Opening balance	(11,606,177)	(7,704,832)
	Adjustment of sale of marketable securities	900	2,860,258
	Fair value gain/(loss) on marketable securities D/Y (Note - 18a.2.1)	(2,533,327)	(7,195,085)
	Transferred to deferred tax assets/(liabilities)	253,243	433,483
		<b>(13,885,362)</b>	<b>(11,606,177)</b>
<b>18a.2.1</b>	<b>Fair value gain/(loss) on marketable securities during the period</b>		
	Unrealized gain/(loss) position (closing)	(15,428,180)	(12,895,753)
	Unrealized gain/(loss) position (opening)	(12,895,753)	(8,560,925)
	Fair value adjustment for sale of securities realized	(900)	(2,860,258)
	<b>Unrealized gain/(loss) during the period</b>	<b>(2,533,327)</b>	<b>(7,195,085)</b>
<b>18a.3</b>	<b>Share of other comprehensive income</b>		
	Opening balance	6,774,874	6,737,875
	Add: Addition during the period	20,992	36,999
		<b>6,795,866</b>	<b>6,774,874</b>
<b>18a.4</b>	<b>Revaluation surplus on property, plant &amp; equipment</b>		
	Opening balance	1,304,880,755	1,310,200,284
	Adjustment during the period to retained earnings for depreciation	(1,408,111)	(6,258,270)
	Adjustment of deferred tax on revaluation surplus	211,217	938,741
		<b>1,303,683,861</b>	<b>1,304,880,755</b>
<b>19.</b>	<b>Retained earnings</b>		
	Opening balance	7,499,339,162	7,400,327,363
	Net profit after tax	55,395,673	318,117,433
	Dividend for the period	-	(234,000,000)
	Adjustment for depreciation on revaluation surplus	3,256,392	14,040,509
	Adjustment for Right of use Assets	-	853,857
		<b>7,557,991,228</b>	<b>7,499,339,162</b>
<b>19.a</b>	<b>Retained Earnings</b>		
	Opening balance	961,565,844	973,857,096
	Net profit after tax	74,848,571	214,596,621
	Dividend for the period	-	(234,000,000)
	Adjustment for depreciation on revaluation surplus	1,408,111	6,258,270
	Adjustment for Right of use Assets	-	853,857
		<b>1,037,822,526</b>	<b>961,565,844</b>
<b>20.</b>	<b>Non-controlling interest</b>		
	Opening balance	1,543,272,725	1,509,624,870
	Share of operating profit	(5,597,796)	33,647,855
	Closing balance	<b>1,537,674,930</b>	<b>1,543,272,725</b>
<b>21</b>	<b>Syndicated loan and other long term loans</b>		
	Agrani Bank Ltd. -BMRE	4,869,164,394	4,737,011,986
	Social Islami Bank Ltd	1,459,726,800	1,425,931,955
	Term Loan -SBLC Agrani Bank Ltd	3,540,000,000	3,540,000,000
	Term Loan Capital Machinery - UPAS L/C	-	37,996,000
	AL-Arafa Islami Bank Ltd.	2,269,160,158	2,217,169,601
	ODDO BHF AG Finance	67,349,871	67,349,871
	Rupali Bank Ltd.	2,879,489,944	2,786,902,839
	Janata Bank Ltd	4,775,837,130	4,598,670,931
	Agrani Bank Ltd.	2,553,270,427	2,520,037,506

SL No.	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
		<b>22,413,998,725</b>	<b>21,931,070,689</b>
	Less: Current portion of long term loan (Note 21.1)	(67,349,871)	(67,349,871)
		<b>22,346,648,853</b>	<b>21,863,720,817</b>
<b>21.1</b>	<b>Current portion of long term loan</b>		
	ODDO BHF AG Finance	67,349,871	67,349,871
		<b>67,349,871</b>	<b>67,349,871</b>
<b>21.a</b>	<b>Long term loan</b>		
	Agrani Bank Ltd. -BMRE	4,869,164,394	4,737,011,986
	Social Islami Bank Ltd.	1,459,726,800	1,425,931,955
	Term Loan -SBLC Agrani Bank Ltd.	3,540,000,000	3,540,000,000
	Term Loan Capital Machinery - UPAS L/C	-	37,996,000
	AL-Arafa Islami Bank Ltd.	2,269,160,158	2,217,169,601
	ODDO BHF AG Finance	67,349,871	67,349,871
	Rupali Bank Ltd.	2,879,489,944	2,786,902,839
	Janata Bank Ltd	4,775,837,130	4,598,670,931
	Agrani Bank Ltd.	2,553,270,427	2,520,037,506
		<b>22,413,998,725</b>	<b>21,931,070,689</b>
	Less: Current portion of long term loan (Note 21.a.1)	(67,349,871)	(67,349,871)
		<b>22,346,648,853</b>	<b>21,863,720,817</b>
<b>21.a.1</b>	<b>Current portion long term loan</b>		
	ODDO BHF AG Finance	67,349,871	67,349,871
		<b>67,349,871</b>	<b>67,349,871</b>
<b>22</b>	<b>Lease obligation</b>		
	Phoenix Finance & Investment Ltd.	-	272,122
	Lease obligation (Office rent)	24,096,347	27,385,897
		<b>24,096,347</b>	<b>27,658,019</b>
	Current portion of lease obligation (22.1)	(12,453,851)	(13,943,551)
		<b>11,642,496</b>	<b>13,714,468</b>
<b>22.1</b>	<b>Current portion of lease obligation</b>		
	Phoenix Finance & Investment Ltd.	-	272,122
	Lease obligation (Office rent)	12,453,851	13,671,429
		<b>12,453,851</b>	<b>13,943,551</b>
<b>23</b>	<b>Deferred tax liability</b>		
	Opening balance	315,432,155	157,696,141
	Adjustment for deferred tax expenses /(income) (Note-23.1)	19,561,578	159,108,238
	Adjustment for deferred tax on revaluation surplus (Note-23.2)	(464,459)	(1,372,223)
		<b>334,529,274</b>	<b>315,432,156</b>
<b>23.1</b>	<b>Adjustment during the year on deferred tax on PPE</b>		
	Deferred tax liability on PPE (closing)	288,872,783	269,311,204
	Deferred tax liability on PPE (opening)	269,311,204	110,202,966
	<b>Deferred tax expenses/(income)</b>	<b>19,561,578</b>	<b>159,108,238</b>

Particular	WDV as on 30 September 2024		Amount in BDT	
	Tax Base	Accounting Base	Deferred Tax Liability as on 30 September 2024	Deferred Tax Liability as on 30 June 2024

SL No.	Particulars			Amount in BDT	
				30-Sep-24	30-Jun-24
	Written down value of property, plant and equipment	9,666,361,203	10,950,240,237	(288,872,783)	(269,311,204)
<b>23.2</b>	<b>Adjustment of deferred tax on revaluation Surplus</b>				
	Deferred tax liability on revaluation surplus (Closing) (Note-23.2.1)			45,656,492	46,120,951
	Deferred tax liability on revaluation surplus (Opening)			46,120,951	47,493,175
	<b>Deferred tax expenses/(income)</b>			<b>(464,459)</b>	<b>(1,372,223)</b>
<b>23.2.1</b>	<b>Adjustment of deferred tax on revaluation surplus</b>				
	Particulars	WDV as on 30 September 2024		Amount in BDT	
		Tax Base	Accounting Base	Deferred Tax Liability as on 30 September 2024	Deferred Tax Liability as on 30 June 2024
	Revaluation reserved on land & land development	-	1,298,728,729	(38,961,862)	(38,961,862)
	Revaluation reserved factory & office building	-	43,296,336	(6,494,450)	(6,660,975)
	Revaluation reserved plant & machinery	-	11,619,985	(1,742,998)	(1,787,690)
	Revaluation reserve on marketable securities	-	(15,428,180)	1,542,818	1,289,575
	<b>Total</b>	<b>-</b>	<b>1,338,216,869</b>	<b>(45,656,492)</b>	<b>(46,120,951)</b>
<b>24.</b>	<b>Short term loans</b>				
	Cash credit (Hypo) Agrani Bank Ltd.			328,344,907	359,821,487
	LTR Agrani Bank Ltd., WASA Corporate Branch			139,354,475	143,233,969
	Loan against marketable securities			53,121,664	53,121,664
				<b>520,821,046</b>	<b>556,177,120</b>
<b>25</b>	<b>Trade and other payables</b>				
	Goods suppliers & manufacturer			5,741,978,529	5,096,894,653
	Other payable			317,514,256	327,752,169
	Current account with inter companies (Note -25.1)			1,053,609,881	1,039,045,934
				<b>7,113,102,666</b>	<b>6,463,692,757</b>
<b>25.1</b>	<b>Current account with inter companies</b>				
	Orion Capital Ltd.			18,420,000	18,420,000
	Orion Oil & Shipping Ltd.			1,032,189,881	1,017,625,934
	Orion Ship Management Ltd.			3,000,000	3,000,000
				<b>1,053,609,881</b>	<b>1,039,045,934</b>
<b>25.a</b>	<b>Trade and other payables</b>				
	Goods suppliers & manufacturer			375,991,371	382,449,535
	Other payables			45,361,268	67,817,868
				<b>421,352,639</b>	<b>450,267,403</b>
<b>26</b>	<b>Employee benefits</b>				
	Workers welfare fund (Note -26.1)			16,302,972	15,817,871
	Bangladesh workers welfare foundation (Note -26.2)			19,432,449	18,947,348
	Workers profit participation fund (Note -26.3)			116,350,044	112,469,233
				<b>152,085,465</b>	<b>147,234,452</b>
<b>26.1</b>	<b>Workers welfare fund</b>				
	Opening balance			15,817,871	13,198,802
	Add: Addition for the period			485,101	2,619,068
	Less: Payment during the period			-	-
				<b>16,302,972</b>	<b>15,817,871</b>

SL No.	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
<b>26.2</b>	<b>Bangladesh workers welfare foundation</b>		
	Opening balance	18,947,348	19,897,506
	Add: Addition for the year	485,101	2,619,068
	Less: Payment during the period	-	(3,569,226)
		<b>19,432,449</b>	<b>18,947,348</b>
<b>26.3</b>	<b>Workers profit participation fund</b>		
	Opening balance	112,469,234	96,300,070
	Add: Addition for the year	3,880,810	20,952,547
	Less: Payment during the period	-	(4,783,384)
		<b>116,350,044</b>	<b>112,469,234</b>
<b>26.a</b>	<b>Employee benefits</b>		
	Workers welfare fund (Note -26.a.1)	5,549,668	5,064,567
	Bangladesh workers welfare foundation (Note -26.a.2)	11,243,320	10,758,218
	Workers profit participation fund (Note -26.a.3)	38,742,165	34,861,355
		<b>55,535,153</b>	<b>50,684,140</b>
<b>26.a.1</b>	<b>Workers welfare fund</b>		
	Opening Balance	5,064,567	3,131,342
	Addition during the period	485,101	1,933,225
	Payment during the period	-	-
		<b>5,549,668</b>	<b>5,064,567</b>
<b>26.a.2</b>	<b>Bangladesh workers welfare foundation</b>		
	Opening balance	10,758,218	10,970,408
	Addition for the period	485,101	1,933,225
	Payment during the period	-	(2,145,415)
		<b>11,243,320</b>	<b>10,758,218</b>
<b>26.a.3</b>	<b>Workers profit participation fund</b>		
	Opening Balance	34,861,355	19,395,555
	Addition during the period	3,880,810	15,465,800
	Payment during the period	-	-
		<b>38,742,165</b>	<b>34,861,355</b>
	WPPF is charged @ 5% of net profit before tax as per labour law Act 2006 (Amended in 2013 ), whereas 80% is allocated to "Workers profit participation fund", 10% to "Employee welfare fund" and 10% to "Bangladesh workers welfare foundation".		
<b>27.</b>	<b>Accrued expenses</b>		
	Salary and wages payable	92,439,853	96,402,075
	Director remuneration payable	15,081,459	11,462,918
	Depot expenses payable	1,653,627	1,813,600
	Telephone & mobile bill payable	4,537,508	4,193,441
	Payable for final settlement of employee	12,364,573	21,598,569
	Utilities payable	13,927,574	11,681,502
	Provision for income tax (Note 27.1)	309,492,400	304,490,093
	Corporate governance audit fees	69,000	69,000
	Statutory Audit fees	1,435,000	1,435,000
	Interest payable on Mashreq Dubai	2,548,000	3,618,656
	Retention money	3,618,656	2,548,000
		<b>457,167,650</b>	<b>459,312,854</b>
<b>27.1</b>	<b>Provision for income tax</b>		



SL No.	Particulars	Amount in BDT	
		30-Sep-24	30-Jun-24
	Opening balance	304,490,093	435,261,134
	Add: Addition during the period	5,002,307	22,154,543
		<b>309,492,400</b>	<b>457,415,677</b>
	Less: Payment/AIT adjustment during the period	-	(152,925,584)
		<b>309,492,400</b>	<b>304,490,093</b>
<b>27.a</b>	<b>Accrued expenses</b>		
	Salary and wages payable	70,078,409	74,620,291
	Director remuneration payable	300,000	300,000
	Depot expenses payable	1,653,627	1,813,600
	Telephone & mobile bill payable	4,537,508	4,193,441
	Payable for final settlement of employee	12,364,573	12,000,037
	Utilities payable	13,927,574	11,681,502
	Provision for income tax (Note - 26.a.1)	309,492,400	304,490,093
	Statutory Audit fees	690,000	690,000
	Corporate governance audit fees	69,000	69,000
		<b>413,113,091</b>	<b>409,857,964</b>
<b>27.a.1</b>	<b>Provision for income tax</b>		
	Opening balance	304,490,093	435,261,134
	Add: Addition during the period	5,002,307	22,154,543
		<b>309,492,400</b>	<b>457,415,677</b>
	Less: Payment/AIT adjustment during the period	-	(152,925,584)
	<b>Closing balance</b>	<b>309,492,400</b>	<b>304,490,093</b>

SL No.	Particulars	Amount in BDT	
		July 2024 to September 2024	July 2023 to September 2023
<b>28. Revenue from net sales</b>			
Local sales		774,550,380	912,430,625
Export sales		55,911,294	19,054,812
Revenue from power generation (Note-28.1)		816,080,138	2,678,166,403
		<b>1,646,541,812</b>	<b>3,609,651,840</b>
<b>28.1 Revenue from power generation</b>			
Reference energy price (variable - O&M)		136,194,815	468,361,231
HFO received from OOSL & BPDB		679,885,323	2,208,984,884
Foreign exchange gain /(loss)		-	820,288
		<b>816,080,138</b>	<b>2,678,166,403</b>
<b>28.a Revenue from net sales</b>			
Local sales		774,550,380	912,430,625
Export sales		55,911,294	19,054,812
		<b>830,461,674</b>	<b>931,485,437</b>
<b>29 Financial expense</b>			
Agrani Bank Limited, Cash Credit (Hypo.)		11,130,436	8,593,720
Agrani Bank Limited, LTR		4,488,924	3,497,234
Phoenix Finance & Investments Ltd.		-	1,971,422
Finance cost on lease obligation (Office rent)		559,035	911,838
Social Islamic Bank Ltd.		33,794,845	-
Bank Charge ,commission & Fees		5,076,283	929,238
Interest on Long Term Borrowing			505,214
		<b>55,049,523</b>	<b>16,408,665</b>
<b>29a Financial expenses</b>			
Agrani Bank Limited, Cash Credit (Hypo.)		11,130,436	8,593,720
Agrani Bank Limited, LTR		4,488,924	3,497,234
Phoenix Finance & Investments Ltd.		-	1,968,160
Finance cost on lease obligation (Office rent)		559,035	911,838
Social Islamic Bank Ltd.		33,794,845	-
Bank Commision, Fees, VAT and Other Charges		-	925,450
		<b>49,973,240</b>	<b>15,896,402</b>
<b>30. Interest &amp; other income</b>			
Interest on FDR		897,328	723,938
Dividend income		430,950	33,075
Others Income		300,226	3,146,767
Gain/(loss) on sale of marketable securities (Note 30.a.1)		(900)	(40,203)
		<b>1,627,604</b>	<b>3,863,577</b>
<b>30.a Interest &amp; other income</b>			
Interest on FDR		897,328	723,938
Dividend income		430,950	33,075
Others Income		300,226	3,146,767
Gain/(loss) on sale of marketable securities (Note 33.a.1)		(900)	(40,203)
		<b>1,627,604</b>	<b>3,863,577</b>
<b>30a.1 Income on sale of marketable securities</b>			
Gain/(loss) on sale of marketable securities		-	-
Interest on portfolio credit and others		(900)	(40,203)
		<b>(900)</b>	<b>(40,203)</b>

SL No.	Particulars	Amount in BDT	
		July 2024 to September 2024	July 2023 to September 2023
<b>31. Current tax</b>			
Profit before tax		97,020,256	156,176,301
Add: Accounting depreciation		144,126,833	70,474,981
Less: Tax depreciation		(228,656,886)	(44,890,313)
Rights og Use Assets		(5,759,253)	-
Taxable income		<b>6,730,951</b>	<b>181,760,970</b>

#### Income tax provision

Particulars	Taxable Income	Taxable Amount	
		30-Sep-24	30-Sep-23
Income tax on taxable profit	(231,942)	(46,388)	39,294,046
Income tax on export net profit	6,531,943	653,194	359,415
Cash Incentive	-	-	875,900
Income tax on dividend received	430,950	86,190	6,615
<b>Total</b>	<b>6,730,951</b>	<b>692,996</b>	<b>40,535,976</b>

#### Minimum Tax

##### Calculation of gross receipt

Revenue from net sales	830,461,674	931,485,437
Interest on FDR	897,328	723,938
Dividend income	430,950	33,075
Others income	300,226	3,146,767
Gain / (loss) on foreign exchange fluctuations	1,627,604	3,863,577
<b>Total Gross Receipts</b>	<b>833,717,782</b>	<b>939,252,793</b>
Minimum Tax (.60% On Total Gross Receipts)	<b>5,002,307</b>	<b>5,635,517</b>
Tax provision whichever is higher	<b>5,002,307</b>	<b>40,535,976</b>

Income tax provision is higher between tax at regular rate on income and minimum tax on gross receipts U/S 163 of ITA 2023. Hence tax at regular rate is accounted for as it is higher than the minimum tax.

#### 32 Earnings per share (EPS)

The computation is given below:

Net profit after tax	55,395,673	176,734,335
Ordinary shares outstanding during the period	234,000,000	234,000,000
<b>Earning per share</b>	<b>0.24</b>	<b>0.76</b>

Consolidated EPS has been decreased to .24 rather than .76 due to decrease of sales as well as power supply of subsidiaries during the period from previous period.

#### 32a Earnings per share

The computation is given below:

Net profit after tax	74,848,571	123,958,725
Ordinary shares outstanding during the period	234,000,000	234,000,000
<b>Earnings per share</b>	<b>0.32</b>	<b>0.53</b>

#### 33. Net Assets Value (NAV) Per Share

Total Assets	53,783,080,016	53,185,508,321
Total Liabilities	32,750,748,174	31,645,931,982
Net Assets	21,032,331,843	21,539,576,339
No of shares	234,000,000	234,000,000
<b>Net Assets Value (NAV) Per Share</b>	<b>89.88</b>	<b>92.05</b>

SL No.	Particulars	Amount in BDT	
		July 2024 to September 2024	July 2023 to September 2023
<b>33a</b>	<b>Net Assets Value (NAV) Per Share</b>		
	Total Assets	38,401,827,403	38,452,129,354
	Total Liabilities	24,237,312,784	23,799,823,138
	Net Assets	14,164,514,619	14,652,306,216
	No of shares	234,000,000	234,000,000
	<b>Net Assets Value (NAV) Per Share</b>	<b>60.53</b>	<b>62.62</b>
<b>34.</b>	<b>Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018:</b>		
	<b>Reconciliation of Net operating cash flow under Indirect Method:</b>		
	<b>Net profit before tax</b>	71,969,562	212,481,768
	Workers profit participation fund	4,851,013	7,808,815
	Interest & other income	(1,627,604)	(3,863,577)
	Financial expenses	55,001,523	16,408,665
	Depreciation	210,103,116	139,975,694
	Increase/(Decrease) in inventory	(91,409,110)	(451,408,303)
	Increase/(Decrease) in receivables	(497,673,242)	(960,303,020)
	Increase/(Decrease) in advance deposit & prepayments	39,992,297	322,916,052
	Increase/(Decrease) in employee benefit	-	2,815,273
	Increase/(Decrease) in payable	647,724,639	1,682,609,520
	Increase/(Decrease) in accrued expenses	5,071,174	666,926
	Income taxes paid	(11,060,095)	(60,590,854)
	<b>Net cash flow from operating Activities</b>	<b>432,943,272</b>	<b>909,516,959</b>
<b>34.1</b>	<b>Net operating cash flow per share</b>	<b>1.85</b>	<b>3.89</b>
	NOCFPS decreased to 1.81 than 3.89 of the previous corresponding period. During the period cash received from customer is decreased than the previous corresponding period.		
<b>34.a</b>	<b>Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018:</b>		
	<b>Reconciliation of Net operating cash flow under Indirect Method:</b>		
	<b>Net profit before tax</b>	97,020,256	156,176,301
	Workers profit participation fund	4,851,013	7,808,815
	Interest & other income	(1,627,604)	(3,863,577)
	Financial expenses	49,973,240	15,896,402
	Depreciation	144,126,833	70,474,981
	Increase/(Decrease) in inventory	54,063,555	70,618,735
	Increase/(Decrease) in receivables	59,497,383	29,977,770
	Increase/(Decrease) in advance, deposit & prepayments	37,310,929	307,851,567
	Increase/(Decrease) in payable	(28,914,764)	51,978,861
	Increase/(Decrease) in accrued expenses	(1,747,180)	666,926
	Income taxes paid	(11,060,095)	(60,590,854)
	<b>Net cash flow from operating activities</b>	<b>403,493,566</b>	<b>646,995,928</b>
<b>34a.1</b>	<b>Net operating cash flow per share</b>	<b>1.72</b>	<b>2.76</b>

Sd/-  
Chairman

Sd/-  
Managing Director

Sd/-  
Director

Sd/-  
Chief Financial Officer

Sd/-  
Company Secretary